Drug Profile
SC 404
Alternative Names: SC-404Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Sancilio & Company
- Class
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Primary sclerosing cholangitis
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Primary sclerosing cholangitis in USA (unspecified route) (Sancilio Company website, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Primary-sclerosing-cholangitis in USA
- 22 Jan 2016 Preclinical trials in Primary sclerosing cholangitis in USA (unspecified route) before January 2016 (Sancilio pipeline; January 2015)